Barclays
ROIV icon

Barclays’s Roivant Sciences ROIV Stock Holding History

Barclays’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Sell
426,685
-989,163
-70% -$29.2M ﹤0.01% 1284
2026
Q1 		$39.2M Buy
1,415,848
+576,569
+69% +$14.8M 0.01% 812
2025
Q4 		$18.2M Sell
839,279
-369,476
-31% -$7.29M ﹤0.01% 1296
2025
Q3 		$18.3M Sell
1,208,755
-906,112
-43% -$11.2M ﹤0.01% 1277
2025
Q2 		$23.8M Buy
2,114,867
+605,951
+40% +$6.57M 0.01% 1032
2025
Q1 		$15.2M Buy
1,508,916
+939,024
+165% +$10.2M ﹤0.01% 1164
2024
Q4 		$6.74M Buy
569,892
+110,371
+24% +$1.3M ﹤0.01% 1893
2024
Q3 		$5.3M Buy
459,521
+75,609
+20% +$861K ﹤0.01% 2046
2024
Q2 		$4.06M Sell
383,912
-63,050
-14% -$691K ﹤0.01% 1664
2024
Q1 		$4.71M Buy
446,962
+52,592
+13% +$567K ﹤0.01% 1897
2023
Q4 		$4.43M Buy
394,370
+24,320
+7% +$237K ﹤0.01% 2207
2023
Q3 		$4.32M Sell
370,050
-20,181
-5% -$228K ﹤0.01% 1403
2023
Q2 		$3.93M Buy
390,231
+158,363
+68% +$1.42M ﹤0.01% 1478
2023
Q1 		$1.71M Buy
231,868
+104,432
+82% +$860K ﹤0.01% 2306
2022
Q4 		$1.02M Buy
127,436
+124,316
+3,984% +$692K ﹤0.01% 2782
2022
Q3 		$10K Sell
3,120
-14,995
-83% -$58.1K ﹤0.01% 4310
2022
Q2 		$74K Buy
18,115
+7,535
+71% +$29.9K ﹤0.01% 3894
2022
Q1 		$52K Buy
+10,580
New +$69.8K ﹤0.01% 4108

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Barclays's ROIV Position: Q2 2026 in Review

Barclays reduced its Roivant Sciences (ROIV) stake by 70% in Q2 2026, selling an estimated $29.2M and leaving 426,685 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Barclays first reported a position in ROIV in Q1 2022 and has held it in 18 quarters since. The position peaked at $39.2M in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Barclays held 426,685 shares of Roivant Sciences worth $15.1M as of Q2 2026.
  • Barclays sold 989,163 Roivant Sciences shares in Q2 2026, an estimated $29.2M.
  • Roivant Sciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1284 holding.
  • Barclays first reported a position in Roivant Sciences in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Roivant Sciences position peaked at $39.2M in Q1 2026.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.